Update on pharmacological therapy for advanced kidney cancer

Authors

Keywords:

advanced renal neoplasm, drug therapy

Abstract

Introduction: renal cell carcinoma is a neoplasm with increasing incidence and mortality worldwide.
Objective: to update the pharmacological treatment of patients with advanced or metastatic renal cell carcinoma and to report on new experimental options.
Methods: a search was carried out in the Medline, Web of Science and other databases, between the years 2018 and 2021 in the Spanish, English, French, German and Portuguese languages. The review was run using the descriptors: kidney cancer, immunotherapy and targeted therapy. Original and review articles, web pages, doctoral and specialty ones and case reports were selected.
Results: targeted therapies are the cornerstone of treatment for advanced or metastatic renal cell carcinoma. Immune checkpoint inhibitors transform your drug treatment and are the basis of most recent research. Adverse events are reported in both options.
Conclusions: investigations are carried out that will provide new options based on combinations of targeted therapies with immunotherapy.

Downloads

Download data is not yet available.

Author Biographies

María Margarita Ríos Cabrera, Hospital Provincial Clínico Quirúrgico Universitario "Arnaldo Milián Castro"

Licenciada en Ciencias Farmacéuticas. Máster en Desarrollo de Medicamentos. Profesora Auxiliar en la Universidad de Ciencias Médicas de Villa Clara.

Iraldo Bello Rivero, Centro de Ingeniería Genética y Biotecnología

Doctor en Ciencias Biológicas. Gerente de Proyectos de Ensayos Clínicos en el CIGB.

Javier Cruz Rodríguez, Hospital Provincial Clínico Quirúrgico Universitario "Arnaldo Milián Castro"

Doctor en Medicina. Especialista de I Grado en Medicina General Integral. Especialista de I Grado en Cirugía General. Máster en Urgencias Médicas. Doctor en Ciencias de la Salud. Profesor Instructor en la Universidad de Ciencias Médicas de Villa Clara. Investigador Auxiliar.

References

1. American Cancer Society [Internet]. Florida: ACS; 2022 [actualizado 12/01/2022; citado 12/01/2022]. Estadísticas importantes sobre el cáncer de riñón; [aprox. 3 pantallas]. Disponible en: https://www.cancer.org/es/cancer/cancer-de-rinon/acerca/estadisticas-clave.html

2. Álvarez Sánchez IM, Polo Rosales Y, Zaragoza Durañona R, Sánchez Lorenzo IM. Características clínicas y epidemiológicas de pacientes con adenocarcinoma de células renales tratados con nefrectomía radical. Rev Electrón Dr. Zoilo E. Marinello Vidaurreta [Internet]. 2020 [citado 12/01/2022];45(6):[aprox. 6 p.]. Disponible en: http://revzoilomarinello.sld.cu/index.php/zmv/article/view/2335

3. Casado Méndez PR, Méndez López VC, Trevín Fernández G, Santos Fonseca RS, Méndez Jiménez O, Ferrer Magadán CE. Características epidemiológicas, formas de presentación y conducta terapéutica en los tumores renales. Rev Cubana Urol [Internet]. 2018 [citado 30/12/2021];7(2):89-98. Disponible en: http://revurologia.sld.cu/index.php/rcu/article/view/329

4. Falcón Maurate JG. Factores pronóstico de sobrevida y de recurrencia del cáncer renal avanzado no metastásico, asociado a trombo tumoral post tratamiento quirúrgico [tesis]. Lima: Universidad Peruana Cayetano Heredia; 2020 [citado 12/01/2022]. Disponible en: https://repositorio.upch.edu.pe/handle/20.500.12866/7952

5. Basterretxea Badiola L. Experiencia de la OSI Donostialdea en el manejo de cáncer renal metastásico entre los años 2001-2012. Análisis retrospectivo, estudio epidemiológico descriptivo y análisis de supervivencia [tesis doctoral]. Leioa: Universidad del País Vasco; 2018 [citado 12/01/2022]. Disponible en: https://addi.ehu.es/handle/10810/34605

6. Sociedad Española de Oncología Médica. La cifras de cáncer en España 2019 [Internet]. Madrid: SEOM; 2019 [citado 12/01/2022]. Disponible en: https://seom.org/images/SEOM_cifras_cancer_2019.pdf

7. Bargues Balanzá M. Factores que influyen en la aportación a la supervivencia de los tratamientos médicos coadyuvantes en el carcinoma renal de células claras después de la nefrectomía radical [tesis]. Salamanca: Universidad de Salamanca; 2018 [citado 12/01/2022]. Disponible en: https://gredos.usal.es/handle/10366/140306

8. Díaz Goizueta FJ. Factores que influyen en la supervivencia a largo plazo en el cáncer renal de células claras después de la nefrectomía radical [tesis]. Salamanca: Universidad de Salamanca; 2018 [citado 12/01/2022]. Disponible en: https://gredos.usal.es/handle/10366/140314

9. Martínez Rodríguez C, Tardáguila de la Fuente G, Villanueva Campos AM. Manejo actual de las masas renales pequeñas. Radiol [Internet]. 2020 [citado 12/01/2022];62(3):167-179. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0033833819301687. https://doi.org/10.1016/j.rx.2019.11.004

10. Vásquez Sullca RR, Balcazar Reyes AD, Yalta Arce H, Allemant Mori LA. Carcinoma renal con cuadro clínico de infección urinaria recurrente en paciente joven. An Fac Med [Internet]. 2019 [citado13/01/2022];80(1):60-63. Disponible en: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/15878. https://doi.org/10.15381/anales.v80i1.15427

11. Zhang Y, Li J, Wang Y. Clear cell sarcoma of the kidney in a 62-year-old patient presenting with generalized pruritus. BMC Cancer [Internet]. 2019 [citado13/01/2022];19:1034. Disponible en: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-6212-1. https://doi.org/10.1186/s12885-019-6212-1

12. Barbas Bernardos G, Herranz Amo F, Caño Velasco J, Gonzalo Balbás A, Subirá Ríos D, Moralejo Gárate M, et al. Influencia de la vía de acceso para la nefrectomía radical en el tratamiento del cáncer renal: estudio comparativo entre cirugía abierta y cirugía laparoscópica. Arch Esp Urol [Internet]. 2020 [citado13/01/2022];73(3):172-182. Disponible en: https://www.aeurologia.com/EN/rich_html/339

13. Ebbing J, Menzel F, Frumento P, Miller K, Ralla B, Fuller TF, et al. Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer. BMC Nephrol [Internet]. 2019 [citado 13/01/2022];20(1):40. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362593/. https://doi.org/10.1186/s12882-019-1215-3

14. Piñón Solis EO, Jiménez Rios MA, Scavuzzo A, Martínez Cervera PF, Aguilar Lima JC. Resultados oncológicos en cáncer de riñón con trombo en vena cava. Experiencia del Instituto Nacional de Cancerología, México. Rev Arg Urol [Internet]. 2020 [citado 13/01/2022];85(3):19-25. Disponible en: https://www.revistasau.org/index.php/revista/article/download/4310/3621

15. Zhuo L, Guodong Z, Xun Z, Shiying T, Peng H, Li Z, et al. A modified surgical technique of shortening renal ischemia time in left renal cancer patients with Mayo level II-IV tumor thrombus. BMC Surg [Internet]. 2020 [citado13/01/2022];20(1):120. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275451/. https://doi.org/10.1186/s12893-020-00769-w

16. Peng J, Dong C, Wang C, Li W, Yu H, Zhang M, et al. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study. Cancer Commun (Lond) [Internet]. 2018 [citado 14/01/2022];38(1):22. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953402/. https://doi.org/10.1186/s40880-018-0292-1

17. Murray R, Zimmerman T, Agarwal A, Palevsky PM, Quaggin S, Rosas SE, et al. Kidney-Related Research in the United States: A Position Statement From the National Kidney Foundation and the American Society of Nephrology. Am J Kidney Dis [Internet]. 2021 [citado 14/01/2022];78(2):161-167. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33984405/. https://doi.org/10.1053/j.ajkd.2021.04.006

18. de Francisco ALM, Macía M, Alonso F, García P, Gutierrez E, Quintana LF, et al. Onco-Nefrología: cáncer, quimioterapia y riñón. Nefrol [Internet]. 2019 [citado 14/01/2022];39(5):455-562. Disponible en: https://www.revistanefrologia.com/es-onco-nefrologia-cancer-quimioterapia-rinon-articulo-S021169951930027X. https://doi.org/10.1016/j.nefro.2018.10.016

19. Iacovelli R, Ciccarese C, Bria E, Bimbatti D, Fantinel E, Mosillo C, et al. Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. Cancer Treat Rev [Internet]. 2018 [citado 14/01/2022];70:112-117. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0305737218301427. https://doi.org/10.1016/j.ctrv.2018.08.007

20. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers [Internet]. 2017 [citado 14/01/2022];3:17009. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936048/. https://doi.org/10.1038/nrdp.2017.9

21. Cancer.net [Internet]. Virginia: ASCO; c2005-2022 [actualizado 01/08/2029; citado 14/01/2022]. Cáncer de riñón: Tipos de tratamiento; [aprox. 10 pantallas]. Disponible en: https://www.cancer.net/es/tipos-de-c%C3%A1ncer/c%C3%A1ncer-de-ri%C3%B1%C3%B3n/tipos-de-tratamiento

22. Pignot G, Gross-Goupil M, Patard JJ. Tratamiento del cáncer de riñón metastásico. EMC Urología [Internet]. 2015 [citado 14/01/2022];47(1):1-13. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1761331015700538. https://doi.org/10.1016/S1761-3310(15)70053-8

23. American Cancer Society [Internet]. Florida: ACS; 2022 [actualizado 12/01/2022; citado 14/01/2022]. Tratamiento del cáncer de riñón; [aprox. 4 pantallas]. Disponible en: https://www.cancer.org/es/cancer/cancer-de-rinon/tratamiento.html

24. Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw [Internet]. 2022 [citado 14/01/2022];20(1):71-90. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34991070/. https://doi.org/10.6004/jnccn.2022.0001

25. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2019 [citado 14/01/2022];30(5):706-720. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30788497/. https://doi.org/10.1093/annonc/mdz056

26. Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM. Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. Mol Cancer Ther [Internet]. 2018 [citado 14/01/2022];17(7):1355-1364. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034114/. https://doi.org/10.1158/1535-7163.mct-17-1299

27. Lalani AKA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, et al. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. European Urology [Internet]. 2019 [citado 14/01/2022];75(1):100-110. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0302283818307516. https://doi.org/10.1016/j.eururo.2018.10.010

28. National Cancer Institute [Internet]. Bethesda: NCI; 2022 [actualizado 08/01/2022; citado 14/01/2022]. Tratamiento del cáncer de células renales (PDQ®)-Versión para profesionales de salud; [aprox. 44 pantallas]. Disponible en: https://www.cancer.gov/espanol/tipos/rinon/pro/tratamiento-rinon-pdq

29. Gill DM, Hahn AW, Hale P, Maughan BL. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Curr Treat Options in Oncol [Internet]. 2018 [citado 14/01/2022];19(1):6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29368125/. https://doi.org/10.1007/s11864-018-0517-1

30. National Cancer Institute [Internet]. Bethesda: NCI; 2022 [actualizado 08/01/2022; citado 14/01/2022]. Inhibidor de puntos de control inmunitario; [aprox. 2 pantallas]. Disponible en: https://www.cancer.gov/espanol/publicaciones/diccionarios/diccionario-cancer/def/inhibidor-de-puntos-de-control-inmunitario

31. Fujiwara R, Inamura K, Yuasa T, Numao N, Yamamoto S, Masuda H, et al. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer. Int J Clin Oncol [Internet]. 2020 [citado 07/03/2022];25(1):151-157. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31522314/. https://doi.org/10.1007/s10147-019-01542-7

32. Wu B, Zhang Q, Sun J. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. J Immunother Cancer [Internet]. 2018 [citado 21/01/2022];6(1):124. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247499/. https://doi.org/10.1186/s40425-018-0440-9

33. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med [Internet]. 2019 [citado 21/01/2022];380(12):1116-1127. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30779529/. https://doi.org/10.1056/nejmoa1816714

34. Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med [Internet]. 2020 [citado 06/03/2021];26(11):1733-1741. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493486/. https://doi.org/10.1038/s41591-020-1044-8

35. Amin A, Hammers H. The Evolving Landscape of Inmunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma. Front Immunol [Internet]. 2019 [citado 21/01/2022];9:3120. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335326/. https://doi.org/10.3389/fimmu.2018.03120

36. Li T, Kang G, Wang T, Huang H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett [Internet]. 2018 [citado 18/01/2022];16(1):687–702. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019900/. https://doi.org/10.3892/ol.2018.8733

37. Canino C, Perrone L, Bosco E, Saltalamacchia G, Mosca A, Rizzo M, et al. Targeting angiogenesis in metastatic renal cell carcinoma. Expert Rev Anticancer Ther [Internet]. 2019 [citado 18/01/2022];19(3):245-257. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30678509/. https://doi.org/10.1080/14737140.2019.1574574

38. Jaiprasart P, Dogra S, Neelakantan D, Devapatla B, Woo S. Identification of signature genes associated with therapeutic resistance to anti-VEGF therapy. Oncotarget [Internet]. 2020 [citado 18/01/2022];11(1):99-114. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967771/. https://doi.org/10.18632/oncotarget.27307

39. Hack SP, Zhu AX, Wang Y. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Front Immunol [Internet]. 2020 [citado 18/01/2022];11:598877. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674951/. https://doi.org/10.3389/fimmu.2018.598877

Downloads

Published

2022-07-22

How to Cite

1.
Ríos Cabrera MM, Bello Rivero I, Cruz Rodríguez J. Update on pharmacological therapy for advanced kidney cancer. Acta Méd Centro [Internet]. 2022 Jul. 22 [cited 2025 Jul. 12];17(1):177-92. Available from: https://revactamedicacentro.sld.cu/index.php/amc/article/view/1674

Issue

Vol. 17 No. 1 (2023): January-March

Section

Review Articles

License

Authors who have publications with this journal agree to the following terms:

  1. Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
  2. Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
  3. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).